This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

OncoMed Pharmaceuticals Presents Updated Phase 1a Data In Advanced Solid Tumor Patients For The First-in-Class WNT-Pathway-Targeting Antibody Vantictumab (OMP-18R5) At The European Cancer Congress 2013

Vantictumab is well tolerated and has surpassed the target efficacious dose from preclinical models

Vantictumab has pharmacodynamic effect on the WNT-pathway and evidence of single-agent activity

Vantictumab is advancing to combination Phase 1b studies in selected tumor types

REDWOOD CITY, Calif., Sept. 29, 2013 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today reported new data for vantictumab, a monoclonal antibody targeting the WNT pathway, at a poster session at the Joint ECCO 17, 38th ESMO and 32nd ESTRO European Cancer Congress 2013 (ECC 2013) in Amsterdam, The Netherlands.

In the ongoing Phase 1a clinical trial, 29 patients with advanced and refractory solid tumors were treated with single-agent vantictumab. To date the drug candidate has been well tolerated up to the current dose of 15 mg/kg every three weeks. This dose of vantictumab is above the target efficacious dose based on minimally passaged human tumor xenograft models. Vantictumab shows pharmacodynamic (PD) effects on the WNT-pathway in patient samples in the Phase 1 clinical trial. Evidence of single-agent activity of vantictumab is noted in several patients with neuroendocrine tumors (NETs). Based on these clinical results and data from preclinical patient-derived tumor models, OncoMed is initiating Phase 1b clinical trials in three tumor indications to study its safety in combination with standard-of-care chemotherapy. Vantictumab is part of OncoMed's Wnt pathway collaboration with Bayer Pharma AG.

Jakob Dupont, M.D., OncoMed's Chief Medical Officer commented, "We are encouraged that vantictumab can be administered safely in this study to patients at doses above the target efficacious doses extrapolated from our preclinical models. These results enable the advancement of vantictumab to three Phase 1b trials later this year."

"With ongoing clinical trials with five novel drug candidates in two key pathways, Notch and WNT, OncoMed is leading the way in the development of anti-cancer stem cell therapies," said Paul J. Hastings, Chairman and Chief Executive Officer of OncoMed.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,598.20 -91.66 -0.52%
S&P 500 2,098.04 -5.80 -0.28%
NASDAQ 5,115.3820 -12.8990 -0.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs